Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics

Molecular Cancer Therapeutics

Volumn 11, Issue 7, 2012, Pages 1400-1410

  Chen, Weizao ^a   Feng, Yang ^a   Zhao, Qi ^a   Zhu, Zhongyu ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FC RECEPTOR; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; SOMATOMEDIN B;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CELL STRAIN MCF 7; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; OLIGOMERIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPES; HUMANS; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR II; NEOPLASMS; PHAGOCYTOSIS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECEPTORS, IGG;

EID: 84863787049     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0172     Document Type: Article

References (30)

1. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24. (Pubitemid 351206693)
2. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47. (Pubitemid 46220849)
3. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 2009;10:1032-40.
4. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64:6252-8. (Pubitemid 39129428)
5. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-20.
6. Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010;16:121-9.
7. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, et al. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 2010;9:1809-19.
8. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI- 573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40.
9. Rehlaender BN, Cho MJ. Anti-drug antibodies as drug carriers. I. For small molecules. Pharm Res 2001;18:745-52. (Pubitemid 32783510)
10. Mihara M, Koishihara Y, Fukui H, Yasukawa K, Ohsugi Y. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 1991;74:55-9.
11. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993;151: 1235-44. (Pubitemid 23219259)
12. May LT, Neta R, Moldawer LL, Kenney JS, Patel K, Sehgal PB. Antibodies chaperone circulating IL-6. Paradoxical effects of anti- IL-6 "neutralizing" antibodies in vivo. J Immunol 1993;151:3225-36. (Pubitemid 23282635)
13. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998;76:231-48. (Pubitemid 28321079)
14. Klein G, Lindahl T, Jondal M, Leibold W, Menezes J, Nilsson K, et al. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow- derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A 1974;71: 3283-6.
15. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 1984;44: 5657-60. (Pubitemid 15183573)
16. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
17. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008;382:779-89.
18. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003;283:17-25. (Pubitemid 37501056)
19. Chen W, Zhu Z, Feng Y, Dimitrov DS. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol Immunol 2010;47:912-21.
20. Zhu Z, Dimitrov DS. Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mol Biol 2009;525:129-42, xv.
21. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006;80:891-9. (Pubitemid 43062901)
22. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 2008;105:17121-6.
23. Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q, et al. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85:9395-405.
24. Zhao Q, Feng Y, Zhu Z, Dimitrov DS. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther 2011;10:1677-85.
25. Singer CF, Mogg M, Koestler W, Pacher M, Marton E, Kubista E, et al. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res 2004;10:4003-9. (Pubitemid 38812474)
26. Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J 1991;5:2684-90. (Pubitemid 21905820)
27. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170:63-70. (Pubitemid 32677567)
28. Childs SG. The pathogenesis of systemic lupus erythematosus. Orthop Nurs 2006;25:140-5; quiz 146-7.
29. Berg M, Uellner R, Langhorne J. Fc gamma receptor II dependency of enhanced presentation of major histocompatibility complex class II peptides by a B cell lymphoma. Eur J Immunol 1997;27:1022-8. (Pubitemid 27153675)
30. Li J, Barreda DR, Zhang YA, Boshra H, Gelman AE, Lapatra S, et al. B lymphocytes from early vertebrates have potent phagocytic and microbicidal abilities. Nat Immunol 2006;7:1116-24. (Pubitemid 44420657)